This is a very nice data about a randomized phase 2 trial. The original study was published in 2023, showing a significant benefit for radiological progression-free survival in oligometastatic-resistant prostate cancer patients treated with SBRT plus abiraterone treatment. And this confirmed that after five years of follow-up there is a significant overall survival benefit in these patients when treated with SBRT if compared to abiraterone alone and this is the first time that a randomized trial showed this kind of benefit in this particular population...
This is a very nice data about a randomized phase 2 trial. The original study was published in 2023, showing a significant benefit for radiological progression-free survival in oligometastatic-resistant prostate cancer patients treated with SBRT plus abiraterone treatment. And this confirmed that after five years of follow-up there is a significant overall survival benefit in these patients when treated with SBRT if compared to abiraterone alone and this is the first time that a randomized trial showed this kind of benefit in this particular population.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
